Drug Trial Radar · NCT05920135
First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Sep 11, 2023
Primary completion
Aug 1, 2026
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Bridge Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, Phase 1/2 study evaluating the safety, tolerability, PK, PD, and preliminary efficacy (antitumor activity) of BBT-207. It will consist of 3 parts; dose escalation, recommended phase 2 dose selection, and dose expansion.
Conditions
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
Interventions
BBT-207Drug
BBT-207 given orally alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Phase 1a dose escalation] Determine Recommended Dose RangeTime frame: Approximately 12 months
- [Phase 1a dose escalation] Incidence of Treatment-Emergent Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, and ≥grade 3 laboratory abnormalities.Time frame: Throughout study completion, approximately 12 months
- [Phase 1b Recommended Phase 2 Dose selection] Determine the RP2DTime frame: Approximately 12 months
- [Phase 2 dose expansion] Evaluate preliminary antitumor activityTime frame: Approximately 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.